




Belgian Cancer Registry

CANCER FACT SHEET 2022

GASTRIC CANCER

ICD-10 C16.1-C16.9



CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ($=200 \times 1.05$) and 255/100,000 over 5 years ($=200 \times (1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

GIST: Gastrointestinal stromal tumour

ADC: Adenocarcinoma

NENs: Neuroendocrine neoplasms

Cardia of stomach: is defined as C16.0 by ICD-10, and included in the Cancer Fact Sheet of oesophageal cancer



1. CANCER INCIDENCE	5
1.1. Gastric cancer incidence: by region	5
1.1.1. Gastric cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022.....	5
1.2. Gastric cancer incidence: by tumour stage	7
1.2.1. Gastric cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	7
1.2.2. Gastric cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022	7
1.2.3. Gastric cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	8
1.3. Gastric cancer incidence: by tumour type	9
1.3.1. Gastric cancer incidence by type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	9
1.4. Gastric cancer incidence: by tumour type and tumour stage	10
1.4.1. Gastric cancer incidence by type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	10
2. CANCER INCIDENCE TRENDS	11
2.1. Gastric cancer incidence trends: by region.....	11
2.1.1. Gastric cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	11
2.1.2. Gastric cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	12
2.2. Gastric cancer incidence trends: by tumour stage.....	13
2.2.1. Gastric cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards	13
2.3. Gastric cancer incidence trends: by tumour type	15
2.3.1. Gastric cancer incidence trends by type and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards	15
2.4. Gastric cancer incidence trends: by age group.....	16
2.4.1. Gastric cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	16
2.4.2. Gastric cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	17
3. CANCER PREVALENCE	18
3.1. Gastric cancer prevalence: by region.....	18
3.1.1. Gastric cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022.....	18
4. CANCER SURVIVAL.....	19
4.1. Gastric cancer survival: by region	19

4.1.1. Gastric cancer survival by region, sex and age group: number at risk and net survival probabilities, 2013-2022	19
4.2. Gastric cancer survival: by tumour stage	21
4.2.1. Gastric cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2013-2022	21
4.2.2. Gastric cancer survival by pathological stage (pStage), and sex: number at risk and net survival probabilities, 2013-2022	22
4.2.3. Gastric cancer survival by stage and sex: number at risk and net survival probabilities, 2013-2022.....	23
4.3. Gastric cancer survival: by tumour type and tumour stage	24
4.3.1. Gastric cancer survival by type, stage and sex: number at risk and net survival probabilities, 2013-2022..	24
5. CANCER SURVIVAL TRENDS.....	26
5.1. Gastric cancer survival trends: by tumour stage.....	26
5.1.1. Gastric cancer survival trends by stage and sex: number at risk and net survival probabilities, 2008-2022	26
5.2. Gastric cancer survival trends: by tumour type and tumour stage.....	28
5.2.1. Gastric cancer survival trends by type, stage and sex: number at risk and net survival probabilities, 2008-2022	28
6. CANCER MORTALITY	31
6.1. Gastric cancer mortality: by region.....	31
6.1.1. Gastric cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021	31
7. CANCER MORTALITY TRENDS.....	33
7.1. Gastric cancer mortality trends: by region	33
7.1.1. Gastric cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021	33
7.1.2. Gastric cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021	34

1. CANCER INCIDENCE



1.1. Gastric cancer incidence: by region

1.1.1. Gastric cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Males																						
Belgium	0	0	0	0	1	1	2	4	11	21	30	42	49	65	82	78	60	51	17	1	515	9.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[0.5]	[1.1]	[2.9]	[5.6]	[7.6]	[10.4]	[13.3]	[20.8]	[31.1]	[41.0]	[47.4]	[65.0]	[56.6]	[17.1]	[9.0]	(8.9; 10.6)
Brussels	0	0	0	0	0	0	2	0	1	4	8	8	3	6	2	2	1	5	1	0	43	9.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[3.9]	[0.0]	[2.2]	[9.2]	[19.8]	[23.1]	[10.7]	[28.3]	[12.1]	[16.4]	[12.4]	[98.3]	[46.1]	[0.0]	[7.2]	(6.6; 12.5)
Flanders	0	0	0	0	1	1	0	3	7	7	11	20	27	36	53	48	43	33	8	1	299	9.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.5]	[0.0]	[1.4]	[3.2]	[3.3]	[4.8]	[8.2]	[12.0]	[18.7]	[32.8]	[38.9]	[51.5]	[62.9]	[40.1]	[26.5]	[9.0]	(8.0; 10.1)
Wallonia	0	0	0	0	0	0	0	1	3	10	11	14	19	23	27	28	16	13	8	0	173	10.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[2.6]	[8.3]	[8.8]	[11.2]	[16.4]	[23.2]	[31.5]	[51.3]	[45.8]	[62.2]	[100.9]	[0.0]	[9.7]	(9.3; 12.6)
Females																						
Belgium	0	0	0	0	1	1	5	9	14	16	32	35	39	49	56	46	45	48	23	2	421	6.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[1.3]	[2.4]	[3.7]	[4.4]	[8.3]	[8.8]	[10.4]	[14.7]	[19.0]	[19.9]	[25.3]	[35.6]	[33.1]	[9.7]	[7.2]	(6.0; 7.3)
Brussels	0	0	0	0	0	0	1	2	3	3	3	5	6	3	4	4	4	5	0	0	43	8.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.9]	[4.2]	[6.7]	[7.5]	[8.0]	[14.8]	[20.2]	[12.0]	[18.8]	[23.2]	[30.7]	[49.7]	[0.0]	[0.0]	[6.9]	(5.7; 10.7)

Region	N [CR]																				All ages	ESR2013 (95%CI)
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		
Flanders	0	0	0	0	0	0	0	5	10	9	17	19	25	24	32	24	29	33	16	0	243	6.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.4]	[4.6]	[4.4]	[7.5]	[8.0]	[11.1]	[12.1]	[18.4]	[16.8]	[25.9]	[38.8]	[37.6]	[0.0]	[7.2]	(5.5; 7.1)
Wallonia	0	0	0	0	1	1	4	2	1	4	12	11	8	22	20	18	12	10	7	2	135	6.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.9]	[3.4]	[1.7]	[0.9]	[3.3]	[9.7]	[8.7]	[6.5]	[20.0]	[19.9]	[25.4]	[22.6]	[25.3]	[33.3]	[31.4]	[7.2]	(5.6; 7.9)

1.2. Gastric cancer incidence: by tumour stage

1.2.1. Gastric cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	17 [0.5]	28 [3.0]	36 [8.3]	81 [1.4]	1.5 (1.2; 1.9)	20 [0.6]	19 [1.9]	25 [3.9]	64 [1.1]	1.0 (0.8; 1.3)
II	11 [0.3]	27 [2.9]	35 [8.1]	73 [1.3]	1.4 (1.1; 1.7)	12 [0.4]	18 [1.8]	32 [5.0]	62 [1.1]	0.9 (0.7; 1.2)
III	9 [0.3]	20 [2.1]	13 [3.0]	42 [0.7]	0.8 (0.5; 1.0)	6 [0.2]	7 [0.7]	18 [2.8]	31 [0.5]	0.5 (0.3; 0.6)
IV	26 [0.8]	51 [5.4]	54 [12.5]	131 [2.3]	2.5 (2.0; 2.9)	26 [0.8]	31 [3.1]	33 [5.2]	90 [1.5]	1.4 (1.1; 1.7)
X/NA	17 [0.5]	23 [2.4]	39 [9.0]	79 [1.4]	1.5 (1.2; 1.9)	13 [0.4]	11 [1.1]	33 [5.2]	57 [1.0]	0.8 (0.6; 1.1)

Note: Excluding gastrointestinal stromal tumours (GIST)

1.2.2. Gastric cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	16 [0.5]	29 [3.1]	22 [5.1]	67 [1.2]	1.2 (0.9; 1.5)	18 [0.5]	21 [2.1]	22 [3.5]	61 [1.0]	1.0 (0.7; 1.2)
II	7 [0.2]	22 [2.3]	20 [4.6]	49 [0.9]	0.9 (0.7; 1.2)	10 [0.3]	9 [0.9]	21 [3.3]	40 [0.7]	0.6 (0.4; 0.8)
III	10 [0.3]	15 [1.6]	17 [3.9]	42 [0.7]	0.8 (0.6; 1.0)	10 [0.3]	7 [0.7]	14 [2.2]	31 [0.5]	0.5 (0.3; 0.7)
IV	13 [0.4]	13 [1.4]	8 [1.9]	34 [0.6]	0.6 (0.4; 0.8)	13 [0.4]	13 [1.3]	3 [0.5]	29 [0.5]	0.5 (0.3; 0.7)
X/NA	34 [1.0]	70 [7.4]	110 [25.5]	214 [3.7]	4.1 (3.6; 4.7)	26 [0.8]	36 [3.6]	81 [12.8]	143 [2.4]	2.1 (1.8; 2.5)

Note: Excluding gastrointestinal stromal tumours (GIST)

1.2.3. Gastric cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	21 [0.6]	33 [3.5]	37 [8.6]	91 [1.6]	1.7 (1.4; 2.1)	23 [0.7]	19 [1.9]	32 [5.0]	74 [1.3]	1.2 (0.9; 1.4)
II	12 [0.4]	30 [3.2]	33 [7.7]	75 [1.3]	1.4 (1.1; 1.7)	13 [0.4]	19 [1.9]	31 [4.9]	63 [1.1]	1.0 (0.7; 1.2)
III	12 [0.4]	22 [2.3]	19 [4.4]	53 [0.9]	1.0 (0.7; 1.3)	8 [0.2]	7 [0.7]	22 [3.5]	37 [0.6]	0.6 (0.4; 0.7)
IV	27 [0.8]	52 [5.5]	58 [13.5]	137 [2.4]	2.6 (2.1; 3.0)	27 [0.8]	32 [3.2]	34 [5.4]	93 [1.6]	1.5 (1.2; 1.8)
X/NA	8 [0.2]	12 [1.3]	30 [7.0]	50 [0.9]	1.0 (0.7; 1.3)	6 [0.2]	9 [0.9]	22 [3.5]	37 [0.6]	0.5 (0.4; 0.7)

Note: Excluding gastrointestinal stromal tumours (GIST)

1.3. Gastric cancer incidence: by tumour type

1.3.1. Gastric cancer incidence by type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Type	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
GIST	32 [1.0]	47 [5.0]	30 [7.0]	109 [1.9]	2.0 (1.6; 2.4)	36 [1.1]	58 [5.8]	23 [3.6]	117 [2.0]	1.9 (1.6; 2.3)
ADC	65 [1.9]	132 [14.0]	163 [37.8]	360 [6.3]	6.9 (6.1; 7.6)	51 [1.5]	72 [7.2]	122 [19.2]	245 [4.2]	3.7 (3.3; 4.2)
NENs	14 [0.4]	13 [1.4]	7 [1.6]	34 [0.6]	0.6 (0.4; 0.8)	22 [0.7]	11 [1.1]	9 [1.4]	42 [0.7]	0.7 (0.5; 0.9)
Other	1 [0.0]	4 [0.4]	7 [1.6]	12 [0.2]	0.2 (0.1; 0.4)	4 [0.1]	3 [0.3]	10 [1.6]	17 [0.3]	0.3 (0.1; 0.4)

1.4. Gastric cancer incidence: by tumour type and tumour stage

1.4.1. Gastric cancer incidence by type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Type	Stage	Males					Females				
		N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
		15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
GIST	X/NA	32 [1.0]	47 [5.0]	30 [7.0]	109 [1.9]	2.0 (1.6; 2.4)	36 [1.1]	58 [5.8]	23 [3.6]	117 [2.0]	1.9 (1.6; 2.3)
ADC	I	14 [0.4]	28 [3.0]	34 [7.9]	76 [1.3]	1.4 (1.1; 1.8)	9 [0.3]	13 [1.3]	27 [4.3]	49 [0.8]	0.7 (0.5; 1.0)
	II	10 [0.3]	29 [3.1]	29 [6.7]	68 [1.2]	1.3 (1.0; 1.6)	9 [0.3]	17 [1.7]	29 [4.6]	55 [0.9]	0.8 (0.6; 1.0)
	III	11 [0.3]	20 [2.1]	19 [4.4]	50 [0.9]	0.9 (0.7; 1.2)	8 [0.2]	6 [0.6]	21 [3.3]	35 [0.6]	0.5 (0.3; 0.7)
	IV	25 [0.7]	47 [5.0]	55 [12.8]	127 [2.2]	2.4 (2.0; 2.8)	23 [0.7]	31 [3.1]	28 [4.4]	82 [1.4]	1.3 (1.0; 1.6)
	X/NA	5 [0.1]	8 [0.8]	26 [6.0]	39 [0.7]	0.8 (0.5; 1.1)	2 [0.1]	5 [0.5]	17 [2.7]	24 [0.4]	0.3 (0.2; 0.5)
NENs	I	7 [0.2]	5 [0.5]	2 [0.5]	14 [0.2]	0.2 (0.1; 0.4)	14 [0.4]	6 [0.6]	5 [0.8]	25 [0.4]	0.4 (0.3; 0.6)
	II	2 [0.1]	1 [0.1]	1 [0.2]	4 [0.1]	0.1 (0.0; 0.1)	3 [0.1]	2 [0.2]	0 [0.0]	5 [0.1]	0.1 (0.0; 0.2)
	III	1 [0.0]	0 [0.0]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.1)
	IV	1 [0.0]	3 [0.3]	3 [0.7]	7 [0.1]	0.1 (0.0; 0.2)	2 [0.1]	0 [0.0]	1 [0.2]	3 [0.1]	0.1 (0.0; 0.1)
	X/NA	3 [0.1]	4 [0.4]	1 [0.2]	8 [0.1]	0.1 (0.0; 0.2)	3 [0.1]	3 [0.3]	2 [0.3]	8 [0.1]	0.1 (0.0; 0.2)
Other	I	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	II	0 [0.0]	0 [0.0]	3 [0.7]	3 [0.1]	0.1 (0.0; 0.1)	1 [0.0]	0 [0.0]	2 [0.3]	3 [0.1]	0.0 (0.0; 0.1)
	III	0 [0.0]	2 [0.2]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	1 [0.1]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.0)
	IV	1 [0.0]	2 [0.2]	0 [0.0]	3 [0.1]	0.1 (0.0; 0.1)	2 [0.1]	1 [0.1]	5 [0.8]	8 [0.1]	0.1 (0.0; 0.2)
	X/NA	0 [0.0]	0 [0.0]	3 [0.7]	3 [0.1]	0.1 (0.0; 0.1)	1 [0.0]	1 [0.1]	3 [0.5]	5 [0.1]	0.1 (0.0; 0.1)

2. CANCER INCIDENCE TRENDS



2.1. Gastric cancer incidence trends: by region

2.1.1. Gastric cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
Belgium	N	663	665	640	622	612	573	564	630	615	593	538	524	558	539	566	542	484	507	515		
	CR	13.0	13.0	12.4	12.0	11.7	10.9	10.6	11.7	11.4	10.9	9.8	9.5	10.1	9.7	10.1	9.6	8.6	8.9	9.0		
	ESR2013	17.8	17.5	17.1	15.3	15.2	14.2	13.3	14.6	14.1	13.4	11.6	11.2	11.5	11.3	11.5	10.8	9.5	9.8	9.7	-3.4 (-3.8; -3.0)	2004-2022
Brussels	N	55	57	59	60	53	42	50	63	54	49	55	48	57	46	52	59	48	46	43		
	CR	11.5	11.8	12.0	12.1	10.5	8.1	9.5	11.6	9.8	8.7	9.7	8.4	9.8	7.9	8.9	10.0	8.0	7.7	7.2		
	ESR2013	16.9	16.9	18.8	16.9	15.6	12.4	14.2	18.8	15.4	14.0	15.6	13.1	14.5	11.6	13.0	14.8	12.4	11.6	9.5	-2.4 (-3.4; -1.3)	2004-2022
Flanders	N	399	416	393	389	397	369	367	382	373	386	348	325	322	322	361	308	305	310	299		
	CR	13.4	14.0	13.1	12.9	13.1	12.0	11.9	12.3	11.9	12.2	11.0	10.2	10.1	10.0	11.1	9.4	9.3	9.4	9.0		
	ESR2013	17.8	18.4	17.1	15.9	16.2	15.2	14.2	14.0	14.0	14.3	12.3	11.2	10.8	10.9	11.8	9.8	9.6	9.5	9.0	-3.9 (-4.3; -3.5)	2004-2022
Wallonia	N	209	192	188	173	162	162	147	185	188	158	135	151	179	171	153	175	131	151	173		
	CR	12.7	11.7	11.3	10.4	9.7	9.6	8.6	10.8	10.9	9.1	7.7	8.6	10.2	9.7	8.6	9.9	7.4	8.5	9.7		
	ESR2013	18.0	15.8	16.7	13.7	13.2	12.8	11.2	14.5	14.0	11.4	9.1	10.4	12.1	11.7	10.1	11.6	8.4	9.7	10.9	-2.9 (-3.9; -1.8)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Gastric cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
Belgium	N	462	456	489	435	481	477	475	477	442	444	475	433	457	393	446	422	352	428	421		
	CR	8.7	8.5	9.1	8.1	8.8	8.7	8.6	8.5	7.9	7.9	8.4	7.6	8.0	6.8	7.7	7.3	6.0	7.3	7.2		
	ESR2013	8.7	8.4	8.8	7.9	8.5	8.4	8.1	8.1	7.3	7.4	8.0	7.1	7.5	6.4	7.2	6.7	5.6	6.9	6.6	-1.9 (-2.4; -1.3)	2004-2022
Brussels	N	30	36	29	37	57	51	48	37	38	43	51	35	53	46	65	45	52	49	43		
	CR	5.8	6.9	5.5	6.9	10.5	9.2	8.5	6.4	6.5	7.3	8.5	5.8	8.7	7.6	10.6	7.3	8.4	7.9	6.9		
	ESR2013	5.9	7.4	5.5	7.4	12.3	9.8	9.6	7.0	7.0	8.8	10.1	7.0	10.5	9.3	12.7	8.6	10.1	9.5	8.2	1.9 (0.0; 3.8)	2004-2022
Flanders	N	302	297	311	271	280	306	291	279	279	262	282	273	259	231	232	252	200	247	243		
	CR	9.9	9.7	10.1	8.7	9.0	9.7	9.2	8.7	8.7	8.1	8.7	8.4	7.9	7.0	7.0	7.6	6.0	7.4	7.2		
	ESR2013	9.8	9.6	9.8	8.5	8.4	9.2	8.5	8.1	7.8	7.4	8.0	7.4	7.0	6.2	6.2	6.5	5.2	6.5	6.3	-2.9 (-3.5; -2.3)	2004-2022
Wallonia	N	130	123	149	127	144	120	136	161	125	139	142	125	145	116	149	125	100	132	135		
	CR	7.5	7.0	8.5	7.2	8.1	6.7	7.6	8.9	6.9	7.6	7.7	6.8	7.9	6.3	8.0	6.7	5.4	7.1	7.2		
	ESR2013	7.6	6.8	8.2	7.2	8.0	6.6	7.3	8.7	6.5	7.2	7.5	6.6	7.5	6.0	7.7	6.3	5.0	6.8	6.8	-1.1 (-2.0; -0.1)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Gastric cancer incidence trends: by tumour stage

2.2.1. Gastric cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards

Stage	Males							Females								
	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period		
I	N	66	98	77	81	91		58	84	56	79	74				
	CR	1.2	1.7	1.4	1.4	1.6		1.0	1.4	1.0	1.4	1.3				
	ESR2013	1.4	2.0	1.5	1.6	1.7	-3.6 (-4.9; -2.2)	2004-2022	0.9	1.3	0.9	1.3	1.2	-2.0 (-3.5; -0.4)	2004-2022	
II	N	89	69	66	60	75		60	44	43	54	63				
	CR	1.6	1.2	1.2	1.1	1.3		1.0	0.8	0.7	0.9	1.1				
	ESR2013		1.8	1.4	1.3	1.2	1.4	-0.4 (-2.0; 1.2)	2004-2022	1.0	0.7	0.7	0.8	1.0	0.5 (-1.0; 2.1)	2004-2022
								7.3 (3.0; 11.7)	2004-2012						5.7 (1.6; 10.0)	2004-2012
							-6.1 (-9.0; -3.1)	2013-2022						-3.4 (-6.4; -0.4)	2013-2022	
III	N	84	76	57	65	53		59	49	41	36	37				
	CR	1.5	1.4	1.0	1.1	0.9		1.0	0.8	0.7	0.6	0.6				
	ESR2013	1.7	1.5	1.1	1.3	1.0	-3.3 (-4.7; -1.8)	2004-2022	0.9	0.8	0.6	0.6	0.6	-2.0 (-3.0; -0.9)	2004-2022	
														0.3 (-1.5; 2.2)	2004-2015	
														-5.5 (-8.4; -2.5)	2016-2022	
IV	N	157	157	157	148	137		98	92	90	115	93				
	CR	2.8	2.8	2.8	2.6	2.4		1.7	1.6	1.5	2.0	1.6				
	ESR2013		3.1	3.1	3.0	2.9	2.6	-1.7 (-2.2; -1.1)	2004-2022	1.6	1.5	1.5	1.9	1.5	-0.5 (-1.5; 0.4)	2004-2022
								-4.3 (-5.7; -2.8)	2004-2012							
							0.5 (-0.7; 1.6)	2013-2022								
X/NA	N	53	48	39	28	50		56	48	42	27	37				
	CR	0.9	0.9	0.7	0.5	0.9		1.0	0.8	0.7	0.5	0.6				

Stage	Males							Females						
	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
ESR2013	1.2	1.0	0.8	0.5	1.0	-12.0 (-13.4; -10.5)	2004-2022	0.8	0.7	0.6	0.4	0.5	-10.2 (-11.9; -8.4)	2004-2022
													-5.7 (-15.2; 4.9)	2004-2008
													-9.6 (-16.9; -1.7)	2009-2012
													-12.1 (-15.0; -9.1)	2013-2022

Note: Excluding gastrointestinal stromal tumours (GIST)

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Gastric cancer incidence trends: by tumour type

2.3.1. Gastric cancer incidence trends by type and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards

Type	Males							Females							
	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
GIST	N	117	94	88	125	109			115	105	80	117	117		
	CR	2.1	1.7	1.6	2.2	1.9			2.0	1.8	1.4	2.0	2.0		
	ESR2013	2.3	1.8	1.7	2.3	2.0	3.8 (2.8; 4.8)	2004-2022	1.9	1.8	1.3	1.9	1.9	5.2 (3.9; 6.6)	2004-2022
						6.2 (4.5; 7.9)	2004-2015						9.2 (6.5; 12.1)	2004-2014	
						0.1 (-2.6; 2.9)	2016-2022						0.4 (-2.9; 3.8)	2015-2022	
ADC	N	409	405	357	333	360			294	268	227	266	245		
	CR	7.3	7.2	6.3	5.9	6.3			5.1	4.6	3.9	4.6	4.2		
	ESR2013	8.4	8.2	7.0	6.5	6.9	-4.8 (-5.2; -4.3)	2004-2022	4.6	4.1	3.5	4.2	3.7	-3.9 (-4.4; -3.3)	2004-2022
NENs	N	27	31	26	34	34			27	41	35	37	42		
	CR	0.5	0.6	0.5	0.6	0.6			0.5	0.7	0.6	0.6	0.7		
	ESR2013	0.5	0.6	0.5	0.6	0.6	3.3 (1.4; 5.2)	2004-2022	0.5	0.7	0.6	0.6	0.7	3.1 (1.7; 4.5)	2004-2022
Other	N	13	12	13	15	12			10	8	10	8	17		
	CR	0.2	0.2	0.2	0.3	0.2			0.2	0.1	0.2	0.1	0.3		
	ESR2013	0.3	0.2	0.3	0.3	0.2	-4.3 (-7.0; -1.5)	2004-2022	0.1	0.1	0.1	0.1	0.3	-2.8 (-6.6; 1.1)	2004-2022
						-6.3 (-9.5; -3.0)	2004-2018						-7.3 (-10.5; -4.0)	2004-2020	
						3.2 (-10.6; 19.2)	2019-2022						41.5 (-2.8; 106.0)	2021-2022	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.4. Gastric cancer incidence trends: by age group

2.4.1. Gastric cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
15-59 N	119	140	99	115	103	103	109	118	116	119	96	111	131	123	123	88	83	102	112		
CR	3.7	4.4	3.1	3.6	3.2	3.2	3.3	3.6	3.5	3.6	2.9	3.3	3.9	3.7	3.7	2.6	2.5	3.1	3.3		
ESR2013	4.0	4.6	3.2	3.6	3.2	3.2	3.4	3.7	3.5	3.6	2.9	3.3	3.9	3.7	3.6	2.6	2.5	3.0	3.3	-1.3 (-2.4; -0.2)	2004-2022
60-74 N	264	260	240	234	223	204	194	236	238	223	213	199	196	173	203	217	206	180	196		
CR	38.8	38.0	34.9	33.4	31.3	28.1	26.2	31.2	30.9	28.5	26.7	24.5	23.5	20.2	23.1	24.2	22.5	19.3	20.7		
ESR2013	38.5	37.8	34.9	33.8	32.0	29.0	27.3	32.0	32.3	29.9	27.4	25.8	24.3	20.9	23.5	24.5	22.9	19.5	21.2	-3.3 (-4.0; -2.7)	2004-2022
75+ N	280	265	301	272	285	266	261	276	261	250	229	214	231	243	240	237	195	224	207		
CR	95.5	87.5	95.8	83.5	84.6	77.0	73.7	76.4	70.7	66.5	59.7	54.7	58.5	61.6	60.4	58.7	47.2	53.8	48.0		
ESR2013	101.3	95.7	105.3	84.2	88.4	83.7	75.9	79.5	74.9	70.9	60.2	55.6	58.3	63.0	60.8	57.9	47.3	53.1	47.6	-4.1 (-4.7; -3.5)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.4.2. Gastric cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
15-59 N	79	71	103	82	101	88	82	99	77	96	106	90	98	91	112	81	78	114	113		
CR	2.5	2.3	3.2	2.6	3.2	2.7	2.5	3.0	2.4	2.9	3.2	2.7	3.0	2.8	3.4	2.5	2.4	3.5	3.4		
ESR2013	2.6	2.3	3.3	2.6	3.2	2.8	2.6	3.1	2.4	2.9	3.2	2.7	3.0	2.7	3.4	2.5	2.4	3.4	3.4	0.7 (-0.5; 1.8)	2004-2022
60-74 N	137	138	125	136	129	140	131	134	120	127	150	122	146	128	140	141	116	151	144		
CR	17.7	17.8	16.2	17.4	16.4	17.5	16.2	16.3	14.4	15.0	17.5	14.0	16.4	14.0	14.9	14.7	11.9	15.2	14.3		
ESR2013	17.2	17.3	15.9	17.4	16.4	17.6	16.4	16.4	14.6	15.4	17.8	14.1	16.7	14.2	15.0	14.8	11.9	15.2	14.4	-1.2 (-1.9; -0.5)	2004-2022
75+ N	246	247	261	217	251	249	262	244	245	221	219	221	213	174	194	200	158	163	164		
CR	47.3	46.5	47.9	38.9	44.1	43.1	44.7	41.1	40.8	36.6	35.9	35.8	34.6	28.4	31.7	32.6	25.5	26.3	25.9		
ESR2013	48.1	46.9	47.7	39.2	43.9	43.1	43.7	40.5	39.4	35.4	35.7	35.5	33.4	27.4	30.5	30.9	24.8	26.0	25.0	-3.7 (-4.3; -3.1)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3. CANCER PREVALENCE



3.1. Gastric cancer prevalence: by region

3.1.1. Gastric cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022

Region		Males				Females			
		1-year	5-year	10-year	15-year	1-year	5-year	10-year	15-year
Belgium	N	401	1,346	2,119	2,571	345	1,186	1,970	2,483
	CR	7.0	23.4	36.8	44.6	5.8	20.0	33.2	41.8
	ESR2013	7.4	24.8	39.2	47.8	5.4	18.7	30.8	38.5
Brussels	N	35	134	197	231	37	134	223	274
	CR	5.8	22.0	32.4	38.0	5.8	21.2	35.2	43.3
	ESR2013	7.2	31.9	47.6	56.9	6.9	25.6	43.2	52.6
Flanders	N	236	785	1,230	1,502	202	667	1,116	1,414
	CR	7.0	23.4	36.7	44.8	5.9	19.5	32.6	41.3
	ESR2013	7.0	23.2	36.4	44.6	5.2	17.3	28.5	35.9
Wallonia	N	130	427	692	838	106	385	631	795
	CR	7.2	23.7	38.4	46.5	5.6	20.5	33.6	42.3
	ESR2013	7.9	25.8	42.1	51.5	5.3	19.3	31.5	39.4



4.1. Gastric cancer survival: by region

4.1.1. Gastric cancer survival by region, sex and age group: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	All	9,550	66.5% (65.5%; 67.6%)	50.0% (48.8%; 51.2%)	46.4% (45.1%; 47.8%)	47.3% (44.5%; 50.4%)
Males						
Belgium	All ages	5,318	64.9% (63.6%; 66.3%)	47.5% (46.0%; 49.1%)	43.8% (42.1%; 45.7%)	44.2% (40.2%; 48.5%)
	15-59	1,082	77.5% (75.0%; 80.1%)	60.0% (57.1%; 63.2%)	54.7% (51.6%; 58.0%)	51.4% (47.7%; 55.3%)
	60-74	1,990	71.2% (69.2%; 73.3%)	52.8% (50.5%; 55.3%)	48.8% (46.2%; 51.5%)	45.9% (41.8%; 50.3%)
	75+	2,247	53.4% (51.1%; 55.7%)	36.8% (34.3%; 39.5%)	34.2% (31.2%; 37.6%)	38.8% (30.4%; 49.6%)
Brussels	All ages	499	63.5% (59.2%; 68.1%)	47.6% (42.9%; 52.8%)	41.2% (36.2%; 46.9%)	37.9% (30.6%; 47.0%)
	15-59	165	73.4% (66.9%; 80.5%)	56.5% (49.2%; 64.9%)	50.1% (42.3%; 59.3%)	45.9% (36.7%; 57.4%)
	60-74	195	67.2% (60.8%; 74.4%)	52.3% (45.2%; 60.4%)	41.9% (34.5%; 51.0%)	38.9% (29.4%; 51.3%)
	75+	139	46.5% (38.4%; 56.3%)	31.1% (23.0%; 42.1%)	30.7% (21.3%; 44.2%)	27.6% (13.5%; 56.5%)
Flanders	All ages	3,256	63.3% (61.6%; 65.1%)	44.8% (42.8%; 46.9%)	42.0% (39.7%; 44.5%)	44.1% (38.8%; 50.1%)
	15-59	557	76.9% (73.4%; 80.5%)	59.2% (55.1%; 63.6%)	54.8% (50.5%; 59.5%)	51.7% (46.9%; 57.2%)
	60-74	1,150	70.7% (68.0%; 73.4%)	51.0% (47.9%; 54.2%)	48.8% (45.4%; 52.4%)	45.9% (40.3%; 52.3%)
	75+	1,549	53.0% (50.4%; 55.9%)	35.2% (32.2%; 38.4%)	32.5% (28.9%; 36.5%)	39.8% (29.3%; 54.0%)
Wallonia	All ages	1,563	68.7% (66.4%; 71.2%)	53.1% (50.3%; 56.0%)	48.4% (45.3%; 51.8%)	46.3% (40.1%; 53.5%)

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	15-59	360	80.3% (76.3%; 84.6%)	63.0% (58.1%; 68.4%)	56.7% (51.4%; 62.5%)	53.0% (46.6%; 60.2%)
	60-74	645	73.4% (70.0%; 77.0%)	56.4% (52.4%; 60.7%)	51.0% (46.6%; 55.7%)	48.3% (42.6%; 54.9%)
	75+	559	56.0% (51.6%; 60.7%)	42.8% (37.8%; 48.4%)	40.1% (34.0%; 47.4%)	39.2% (25.7%; 59.9%)
Females						
Belgium	All ages	4,232	68.6% (67.1%; 70.1%)	53.1% (51.3%; 54.8%)	49.7% (47.8%; 51.7%)	51.2% (47.2%; 55.5%)
	15-59	970	84.2% (81.9%; 86.5%)	67.9% (65.0%; 71.0%)	63.0% (59.8%; 66.4%)	60.2% (56.6%; 64.0%)
	60-74	1,350	75.9% (73.6%; 78.3%)	61.7% (58.9%; 64.5%)	58.0% (55.1%; 61.1%)	55.3% (51.2%; 59.7%)
	75+	1,912	55.5% (53.1%; 58.0%)	39.5% (36.8%; 42.4%)	37.1% (33.9%; 40.6%)	43.5% (35.7%; 53.1%)
Brussels	All ages	472	66.9% (62.6%; 71.5%)	51.0% (46.1%; 56.4%)	48.7% (43.3%; 54.8%)	50.5% (40.5%; 62.9%)
	15-59	151	82.9% (77.0%; 89.1%)	66.2% (58.8%; 74.5%)	61.2% (53.4%; 70.1%)	56.8% (48.1%; 67.0%)
	60-74	155	70.2% (63.3%; 78.0%)	56.3% (48.7%; 65.2%)	55.2% (47.2%; 64.6%)	46.1% (34.5%; 61.5%)
	75+	166	49.4% (41.8%; 58.3%)	32.6% (24.7%; 43.0%)	31.6% (22.4%; 44.6%)	52.7% (31.7%; 87.8%)
Flanders	All ages	2,463	68.4% (66.5%; 70.4%)	52.7% (50.4%; 55.1%)	49.2% (46.6%; 52.0%)	52.6% (46.9%; 58.9%)
	15-59	498	82.9% (79.7%; 86.3%)	67.3% (63.2%; 71.7%)	61.8% (57.4%; 66.6%)	60.2% (55.3%; 65.5%)
	60-74	745	76.5% (73.4%; 79.7%)	61.0% (57.3%; 64.9%)	56.7% (52.7%; 61.0%)	57.3% (52.1%; 63.0%)
	75+	1,220	57.6% (54.6%; 60.7%)	41.6% (38.2%; 45.4%)	39.5% (35.4%; 44.0%)	46.4% (36.2%; 59.5%)
Wallonia	All ages	1,297	69.5% (66.9%; 72.1%)	54.5% (51.5%; 57.7%)	51.0% (47.7%; 54.6%)	48.1% (43.1%; 53.7%)
	15-59	321	86.7% (83.0%; 90.5%)	69.7% (64.7%; 75.1%)	65.8% (60.5%; 71.6%)	61.9% (55.7%; 68.7%)
	60-74	450	76.9% (73.1%; 81.0%)	64.7% (60.1%; 69.6%)	61.2% (56.3%; 66.5%)	55.1% (48.0%; 63.2%)
	75+	526	52.6% (48.1%; 57.4%)	36.7% (31.9%; 42.2%)	33.4% (27.9%; 40.0%)	34.2% (24.7%; 47.4%)

4.2. Gastric cancer survival: by tumour stage

4.2.1. Gastric cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022							
cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	7,562	58.4% (57.3%; 59.6%)	44.7% (43.5%; 46.0%)	38.3% (37.0%; 39.6%)	35.3% (34.0%; 36.7%)	33.9% (32.5%; 35.3%)	32.6% (29.7%; 35.8%)
Males							
All	6,966	55.7% (54.5%; 57.0%)	41.3% (40.1%; 42.6%)	35.2% (33.9%; 36.5%)	32.1% (30.8%; 33.5%)	30.6% (29.2%; 32.0%)	25.1% (22.8%; 27.5%)
I	618	83.0% (79.6%; 86.5%)	73.5% (69.3%; 78.0%)	67.9% (63.1%; 73.1%)	66.0% (60.7%; 71.9%)	64.5% (58.4%; 71.3%)	63.6% (47.2%; 85.6%)
II	751	70.6% (67.1%; 74.2%)	54.1% (50.2%; 58.2%)	47.5% (43.5%; 51.9%)	44.4% (40.2%; 49.1%)	40.3% (35.7%; 45.4%)	38.1% (29.7%; 48.9%)
III	409	72.0% (67.5%; 76.9%)	56.3% (51.3%; 61.9%)	48.3% (43.0%; 54.2%)	44.5% (39.0%; 50.9%)	38.9% (32.8%; 46.2%)	40.0% (30.0%; 53.2%)
IV	1,303	31.7% (29.2%; 34.4%)	14.9% (13.0%; 17.1%)	8.3% (6.8%; 10.3%)	5.6% (4.2%; 7.4%)	4.4% (3.2%; 6.2%)	FU<10y
X/NA	1,244	59.6% (56.7%; 62.6%)	47.0% (44.0%; 50.3%)	41.4% (38.3%; 44.8%)	38.2% (35.0%; 41.8%)	37.8% (34.4%; 41.6%)	30.5% (24.4%; 38.2%)
Females							
All	5,237	57.3% (55.9%; 58.7%)	44.8% (43.4%; 46.3%)	38.6% (37.2%; 40.2%)	35.9% (34.4%; 37.5%)	34.4% (32.8%; 36.1%)	34.5% (31.9%; 37.3%)
I	509	86.2% (82.7%; 89.7%)	77.1% (72.8%; 81.7%)	73.2% (68.3%; 78.5%)	69.8% (64.3%; 75.8%)	68.3% (62.2%; 74.9%)	72.3% (60.2%; 86.9%)
II	511	69.2% (65.0%; 73.6%)	54.6% (50.0%; 59.6%)	44.3% (39.6%; 49.7%)	43.0% (38.0%; 48.6%)	40.6% (35.3%; 46.6%)	33.0% (23.6%; 46.0%)
III	273	62.8% (57.0%; 69.1%)	45.0% (39.1%; 51.8%)	38.3% (32.3%; 45.4%)	29.9% (24.0%; 37.4%)	30.6% (24.4%; 38.3%)	28.4% (19.3%; 42.0%)
IV	847	31.9% (28.9%; 35.3%)	15.2% (12.9%; 17.9%)	8.9% (7.0%; 11.3%)	6.9% (5.2%; 9.2%)	5.8% (4.1%; 8.1%)	3.2% (1.2%; 8.8%)
X/NA	1,104	63.4% (60.4%; 66.5%)	53.6% (50.4%; 57.1%)	46.7% (43.3%; 50.3%)	43.4% (39.9%; 47.2%)	42.8% (39.2%; 46.9%)	48.7% (41.0%; 57.9%)

Note: Excluding gastrointestinal stromal tumours (GIST)

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

4.2.2. Gastric cancer survival by pathological stage (pStage), and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022							
pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	7,562	58.4% (57.3%; 59.6%)	44.7% (43.5%; 46.0%)	38.3% (37.0%; 39.6%)	35.3% (34.0%; 36.7%)	33.9% (32.5%; 35.3%)	32.6% (29.7%; 35.8%)
Males							
All	4,322	57.6% (56.0%; 59.2%)	43.3% (41.7%; 44.9%)	37.0% (35.4%; 38.7%)	34.1% (32.4%; 35.9%)	32.3% (30.5%; 34.3%)	29.0% (25.3%; 33.4%)
I	715	93.1% (90.7%; 95.6%)	90.9% (87.8%; 94.1%)	88.3% (84.5%; 92.3%)	86.9% (82.4%; 91.7%)	85.7% (80.4%; 91.3%)	81.2% (67.8%; 97.2%)
II	533	88.9% (85.8%; 92.2%)	77.0% (72.8%; 81.5%)	68.4% (63.5%; 73.6%)	66.2% (60.9%; 71.9%)	62.7% (56.7%; 69.3%)	53.1% (41.0%; 68.7%)
III	597	73.1% (69.3%; 77.0%)	48.5% (44.3%; 53.1%)	35.7% (31.6%; 40.4%)	27.2% (23.2%; 31.8%)	21.8% (17.9%; 26.5%)	19.2% (14.6%; 25.1%)
IV	403	36.0% (31.5%; 41.2%)	14.3% (11.2%; 18.3%)	7.4% (5.2%; 10.7%)	4.7% (2.9%; 7.7%)	3.1% (1.6%; 5.8%)	3.5% (1.9%; 6.6%)
X/NA	2,075	37.0% (34.8%; 39.2%)	22.2% (20.3%; 24.2%)	17.3% (15.5%; 19.4%)	15.4% (13.5%; 17.5%)	15.0% (13.1%; 17.3%)	12.6% (8.5%; 18.6%)
Females							
All	3,240	59.6% (57.8%; 61.4%)	46.7% (44.9%; 48.7%)	40.0% (38.0%; 42.0%)	36.9% (35.0%; 39.0%)	35.9% (33.8%; 38.1%)	37.2% (32.9%; 42.0%)
I	562	96.6% (94.5%; 98.7%)	95.0% (92.2%; 97.9%)	93.8% (90.2%; 97.5%)	92.7% (88.4%; 97.2%)	93.8% (88.8%; 99.2%)	93.8% (76.2%; 115.6%)
II	370	90.0% (86.5%; 93.6%)	79.3% (74.6%; 84.3%)	73.5% (68.1%; 79.3%)	69.5% (63.6%; 76.0%)	66.9% (60.4%; 74.1%)	79.9% (64.9%; 98.4%)
III	385	69.5% (64.8%; 74.5%)	48.1% (43.0%; 53.7%)	32.3% (27.5%; 37.9%)	24.8% (20.2%; 30.5%)	24.5% (19.8%; 30.3%)	17.6% (12.3%; 25.3%)
IV	327	43.0% (37.9%; 48.8%)	19.6% (15.7%; 24.6%)	12.7% (9.3%; 17.3%)	10.2% (7.2%; 14.6%)	8.7% (5.8%; 13.1%)	4.9% (2.2%; 11.0%)
X/NA	1,598	40.6% (38.1%; 43.2%)	27.5% (25.1%; 30.0%)	20.7% (18.5%; 23.2%)	18.2% (16.0%; 20.8%)	16.7% (14.5%; 19.3%)	17.9% (14.3%; 22.5%)

Note: Excluding gastrointestinal stromal tumours (GIST)

4.2.3. Gastric cancer survival by stage and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022							
Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	7,562	58.4% (57.3%; 59.6%)	44.7% (43.5%; 46.0%)	38.3% (37.0%; 39.6%)	35.3% (34.0%; 36.7%)	33.9% (32.5%; 35.3%)	32.6% (29.7%; 35.8%)
Males							
All	4,322	57.6% (56.0%; 59.2%)	43.3% (41.7%; 44.9%)	37.0% (35.4%; 38.7%)	34.1% (32.4%; 35.9%)	32.3% (30.5%; 34.3%)	29.0% (25.3%; 33.4%)
I	815	86.9% (84.1%; 89.7%)	81.2% (77.7%; 84.8%)	77.1% (73.0%; 81.4%)	76.2% (71.6%; 81.1%)	75.7% (70.4%; 81.3%)	73.8% (59.4%; 91.8%)
II	801	75.7% (72.5%; 79.0%)	61.6% (57.9%; 65.5%)	54.2% (50.2%; 58.5%)	51.7% (47.5%; 56.3%)	47.9% (43.2%; 53.0%)	39.7% (31.7%; 49.8%)
III	686	69.6% (66.0%; 73.4%)	48.3% (44.4%; 52.6%)	38.5% (34.6%; 43.0%)	32.1% (28.1%; 36.7%)	27.8% (23.7%; 32.6%)	25.5% (19.8%; 32.9%)
IV	1,410	32.0% (29.6%; 34.6%)	14.8% (12.9%; 16.9%)	8.3% (6.8%; 10.1%)	5.6% (4.3%; 7.3%)	4.5% (3.2%; 6.1%)	3.6% (2.1%; 6.0%)
X/NA	613	40.3% (36.4%; 44.7%)	28.6% (24.8%; 32.9%)	25.2% (21.4%; 29.6%)	22.4% (18.6%; 26.9%)	22.7% (18.7%; 27.5%)	18.5% (12.6%; 27.3%)
Females							
All	3,240	59.6% (57.8%; 61.4%)	46.7% (44.9%; 48.7%)	40.0% (38.0%; 42.0%)	36.9% (35.0%; 39.0%)	35.9% (33.8%; 38.1%)	37.2% (32.9%; 42.0%)
I	675	88.7% (85.9%; 91.6%)	84.3% (80.8%; 87.9%)	81.2% (77.1%; 85.5%)	79.5% (74.8%; 84.4%)	79.7% (74.5%; 85.3%)	80.7% (65.9%; 98.8%)
II	560	77.2% (73.5%; 81.1%)	63.2% (58.8%; 67.9%)	55.7% (51.0%; 60.8%)	54.6% (49.6%; 60.0%)	51.5% (46.3%; 57.4%)	56.9% (45.7%; 70.9%)
III	460	64.8% (60.4%; 69.6%)	45.5% (40.9%; 50.7%)	34.1% (29.5%; 39.3%)	25.8% (21.3%; 31.1%)	26.0% (21.5%; 31.6%)	22.9% (17.3%; 30.3%)
IV	931	32.2% (29.3%; 35.4%)	15.3% (13.1%; 17.9%)	9.1% (7.3%; 11.4%)	7.2% (5.5%; 9.3%)	6.0% (4.4%; 8.1%)	3.8% (1.9%; 7.8%)
X/NA	616	49.0% (44.9%; 53.4%)	38.6% (34.5%; 43.2%)	31.1% (27.0%; 35.8%)	27.2% (23.1%; 32.0%)	26.0% (21.9%; 30.9%)	28.7% (23.3%; 35.4%)

Note: Excluding gastrointestinal stromal tumours (GIST)

4.3. Gastric cancer survival: by tumour type and tumour stage

4.3.1. Gastric cancer survival by type, stage and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022								
Type	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total		9,550	66.5% (65.5%; 67.6%)	55.4% (54.3%; 56.5%)	50.0% (48.8%; 51.2%)	47.6% (46.3%; 48.8%)	46.4% (45.1%; 47.8%)	47.3% (44.5%; 50.4%)
Males								
GIST	All	1,024	96.6% (95.0%; 98.1%)	93.5% (91.3%; 95.8%)	92.2% (89.5%; 95.0%)	92.4% (89.3%; 95.6%)	92.9% (89.4%; 96.6%)	110.3% (100.0%; 121.8%)
ADC	All	3,902	56.0% (54.3%; 57.7%)	40.9% (39.2%; 42.6%)	34.3% (32.6%; 36.1%)	31.2% (29.5%; 33.1%)	29.2% (27.3%; 31.2%)	26.5% (22.7%; 30.9%)
	I	693	85.1% (82.0%; 88.4%)	78.9% (75.0%; 82.9%)	74.3% (69.7%; 79.1%)	73.0% (67.9%; 78.5%)	72.2% (66.5%; 78.5%)	71.9% (56.4%; 91.5%)
	II	751	75.7% (72.4%; 79.1%)	61.4% (57.6%; 65.5%)	53.6% (49.5%; 58.1%)	50.9% (46.6%; 55.7%)	46.8% (42.1%; 52.2%)	39.3% (31.2%; 49.6%)
	III	658	69.8% (66.1%; 73.7%)	47.9% (43.9%; 52.3%)	38.4% (34.4%; 43.0%)	32.2% (28.1%; 36.9%)	27.7% (23.5%; 32.6%)	25.8% (19.9%; 33.4%)
	IV	1,323	32.1% (29.6%; 34.8%)	14.4% (12.6%; 16.6%)	8.1% (6.6%; 10.0%)	5.4% (4.1%; 7.2%)	4.2% (3.0%; 5.9%)	FU<10y
	X/NA	477	29.6% (25.5%; 34.3%)	16.6% (13.1%; 20.9%)	11.7% (8.7%; 15.8%)	8.5% (5.8%; 12.6%)	8.5% (5.7%; 12.6%)	5.7% (2.8%; 11.7%)
NENs	All	297	84.7% (80.4%; 89.3%)	79.0% (73.9%; 84.4%)	76.2% (70.7%; 82.2%)	74.6% (68.6%; 81.2%)	76.3% (69.8%; 83.3%)	65.4% (50.1%; 85.2%)
	I	111	97.5% (93.4%; 101.7%)	95.5% (90.0%; 101.4%)	95.6% (89.3%; 102.3%)	96.9% (90.0%; 104.3%)	97.2% (88.5%; 106.8%)	87.2% (65.3%; 116.4%)
	II	35	N<50	N<50	N<50	N<50	N<50	N<50
	III	11	N<50	N<50	N<50	N<50	N<50	N<50
	IV	44	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	97	87.0% (79.9%; 94.8%)	80.9% (72.3%; 90.5%)	81.7% (72.5%; 92.1%)	78.8% (68.4%; 90.8%)	82.2% (71.1%; 95.1%)	75.2% (50.1%; 113.0%)
Other	All	127	44.7% (36.5%; 54.8%)	32.9% (25.0%; 43.3%)	30.1% (22.0%; 41.0%)	29.6% (21.3%; 41.1%)	27.6% (18.9%; 40.3%)	19.2% (6.6%; 55.5%)
	I	11	N<50	N<50	N<50	N<50	N<50	N<50
	II	15	N<50	N<50	N<50	N<50	N<50	N<50
	III	18	N<50	N<50	N<50	N<50	N<50	N<50
	IV	43	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2013-2022								
Type	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	X/NA	40	N<50	N<50	N<50	N<50	N<50	N<50
Females								
GIST	All	1,012	97.8% (96.5%; 99.1%)	96.8% (95.0%; 98.6%)	95.7% (93.5%; 98.0%)	95.2% (92.3%; 98.2%)	95.1% (91.7%; 98.6%)	97.8% (89.7%; 106.7%)
ADC	All	2,772	56.0% (54.1%; 58.0%)	41.4% (39.4%; 43.4%)	34.0% (32.0%; 36.1%)	30.5% (28.5%; 32.7%)	29.4% (27.3%; 31.7%)	31.1% (26.7%; 36.3%)
	I	496	86.0% (82.5%; 89.7%)	80.1% (75.7%; 84.7%)	75.9% (70.9%; 81.4%)	73.4% (67.7%; 79.5%)	72.5% (66.2%; 79.4%)	75.4% (58.8%; 96.7%)
	II	519	76.0% (72.1%; 80.1%)	61.4% (56.8%; 66.3%)	53.1% (48.2%; 58.4%)	52.3% (47.2%; 57.9%)	50.0% (44.6%; 56.0%)	54.9% (43.5%; 69.4%)
	III	442	65.4% (60.8%; 70.2%)	45.5% (40.8%; 50.8%)	33.5% (28.8%; 38.8%)	24.6% (20.2%; 30.1%)	24.8% (20.2%; 30.4%)	20.8% (15.2%; 28.3%)
	IV	882	32.9% (29.8%; 36.2%)	15.4% (13.1%; 18.1%)	9.1% (7.3%; 11.5%)	7.1% (5.4%; 9.3%)	5.9% (4.3%; 8.1%)	3.8% (1.8%; 7.8%)
	X/NA	433	35.0% (30.5%; 40.2%)	21.4% (17.4%; 26.3%)	13.8% (10.2%; 18.6%)	8.0% (5.2%; 12.4%)	7.1% (4.4%; 11.5%)	11.1% (6.7%; 18.3%)
NENs	All	368	91.6% (88.6%; 94.8%)	91.3% (87.9%; 94.8%)	89.1% (85.1%; 93.4%)	89.2% (84.8%; 93.8%)	88.4% (83.3%; 93.7%)	86.4% (74.6%; 100.1%)
	I	170	98.0% (95.2%; 100.9%)	98.1% (94.6%; 101.7%)	99.6% (95.7%; 103.7%)	99.9% (95.0%; 105.1%)	103.8% (98.7%; 109.2%)	96.9% (73.3%; 128.0%)
	II	29	N<50	N<50	N<50	N<50	N<50	N<50
	III	11	N<50	N<50	N<50	N<50	N<50	N<50
	IV	19	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	139	92.2% (87.3%; 97.3%)	92.2% (86.9%; 97.9%)	84.8% (77.7%; 92.5%)	84.1% (76.6%; 92.3%)	82.0% (73.8%; 91.0%)	81.2% (68.7%; 95.8%)
Other	All	104	43.0% (34.0%; 54.5%)	32.8% (24.1%; 44.5%)	26.0% (17.7%; 38.1%)	25.3% (16.7%; 38.4%)	25.6% (16.7%; 39.4%)	FU<10y
	I	10	N<50	N<50	N<50	N<50	N<50	N<50
	II	13	N<50	N<50	N<50	N<50	N<50	N<50
	III	7	N<50	N<50	N<50	N<50	N<50	N<50
	IV	30	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	44	N<50	N<50	N<50	N<50	N<50	N<50

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

5. CANCER SURVIVAL TRENDS



5.1. Gastric cancer survival trends: by tumour stage

5.1.1. Gastric cancer survival trends by stage and sex: number at risk and net survival probabilities, 2008-2022

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2008-2012	All	2,644	52.7% (50.7%; 54.7%)	32.2% (30.2%; 34.2%)	27.8% (25.8%; 30.0%)	1,997	53.5% (51.3%; 55.9%)	36.5% (34.2%; 38.9%)	32.2% (29.7%; 34.8%)
	I	487	84.2% (80.6%; 88.0%)	74.1% (69.1%; 79.4%)	70.5% (64.7%; 76.8%)	395	88.0% (84.2%; 91.8%)	78.4% (73.1%; 84.0%)	74.7% (68.3%; 81.7%)
	II	437	73.4% (69.1%; 78.1%)	51.9% (46.7%; 57.6%)	45.7% (40.2%; 51.9%)	286	71.6% (66.2%; 77.4%)	53.4% (47.2%; 60.5%)	47.9% (41.0%; 56.0%)
	III	389	63.3% (58.4%; 68.6%)	29.7% (25.1%; 35.2%)	20.0% (15.9%; 25.1%)	242	62.6% (56.5%; 69.2%)	31.2% (25.5%; 38.2%)	22.2% (17.0%; 28.9%)
	IV	669	30.8% (27.3%; 34.6%)	6.5% (4.8%; 8.8%)	4.0% (2.6%; 6.2%)	456	25.1% (21.4%; 29.5%)	5.0% (3.3%; 7.5%)	3.3% (1.9%; 5.7%)
	X/NA	662	31.7% (28.2%; 35.6%)	15.6% (12.7%; 19.2%)	13.2% (10.2%; 17.1%)	619	40.6% (36.8%; 44.9%)	27.2% (23.5%; 31.5%)	22.9% (19.1%; 27.4%)
2013-2017	All	2,248	55.9% (53.7%; 58.1%)	34.8% (32.7%; 37.2%)	30.7% (28.4%; 33.2%)	1,709	58.9% (56.5%; 61.4%)	38.9% (36.4%; 41.6%)	35.1% (32.4%; 37.9%)
	I	403	85.6% (81.6%; 89.7%)	75.1% (69.6%; 81.1%)	74.7% (68.0%; 82.0%)	325	89.8% (85.9%; 93.9%)	82.2% (76.6%; 88.2%)	81.5% (74.8%; 88.9%)
	II	442	75.2% (70.9%; 79.8%)	50.7% (45.6%; 56.3%)	46.3% (40.6%; 52.7%)	297	79.3% (74.4%; 84.5%)	58.5% (52.3%; 65.3%)	55.0% (48.3%; 62.7%)
	III	352	67.6% (62.5%; 73.0%)	33.5% (28.4%; 39.5%)	22.1% (17.5%; 28.0%)	238	62.3% (56.2%; 69.0%)	27.7% (22.3%; 34.5%)	22.2% (17.0%; 28.8%)
	IV	655	28.9% (25.6%; 32.7%)	6.0% (4.2%; 8.3%)	2.6% (1.5%; 4.4%)	443	30.7% (26.6%; 35.4%)	9.3% (6.9%; 12.5%)	5.8% (3.9%; 8.7%)
	X/NA	398	38.1% (33.4%; 43.5%)	25.2% (20.7%; 30.7%)	22.8% (18.0%; 28.7%)	407	47.9% (42.9%; 53.3%)	28.9% (24.2%; 34.4%)	22.7% (18.3%; 28.2%)
2018-2022	All	2,074	59.4% (57.2%; 61.7%)	39.6% (37.2%; 42.2%)	34.0% (31.0%; 37.2%)	1,531	60.4% (57.9%; 63.0%)	41.2% (38.3%; 44.3%)	36.9% (33.5%; 40.7%)
	I	412	88.1% (84.4%; 92.0%)	79.2% (73.4%; 85.4%)	76.1% (67.5%; 85.9%)	350	87.8% (83.8%; 91.9%)	80.2% (74.3%; 86.5%)	76.2% (67.5%; 85.9%)
	II	359	76.3% (71.6%; 81.3%)	59.1% (53.0%; 66.0%)	48.5% (40.7%; 57.7%)	263	74.8% (69.3%; 80.7%)	52.3% (45.3%; 60.4%)	46.5% (38.4%; 56.4%)

Period	Stage	Males				Females			
		N at risk	Net Survival Probability			N at risk	Net Survival Probability		
			1-y (95%CI)	3-y (95%CI)	5-y (95%CI)		1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	III	334	71.7% (66.7%; 77.2%)	44.5% (38.6%; 51.3%)	36.1% (29.4%; 44.4%)	222	67.5% (61.3%; 74.4%)	41.9% (34.9%; 50.4%)	30.8% (23.1%; 41.1%)
	IV	755	34.6% (31.3%; 38.3%)	10.7% (8.5%; 13.6%)	6.8% (4.6%; 9.9%)	488	33.6% (29.5%; 38.1%)	8.8% (6.3%; 12.3%)	6.5% (4.0%; 10.4%)
	X/NA	215	44.4% (37.8%; 52.2%)	24.8% (18.7%; 32.8%)	22.1% (15.8%; 31.0%)	209	51.2% (44.3%; 59.1%)	35.8% (28.3%; 45.4%)	35.4% (27.1%; 46.3%)

Note: Excluding gastrointestinal stromal tumours (GIST)

5.2. Gastric cancer survival trends: by tumour type and tumour stage

5.2.1. Gastric cancer survival trends by type, stage and sex: number at risk and net survival probabilities, 2008-2022

Type	Period	Stage	Males				Females			
			N at risk	Net Survival Probability			N at risk	Net Survival Probability		
			1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)		
GIST	2008-2012	All	331	93.5% (90.3%; 96.9%)	92.5% (87.8%; 97.5%)	91.9% (85.9%; 98.3%)	339	94.7% (91.8%; 97.7%)	93.9% (89.9%; 98.2%)	95.7% (90.7%; 101.0%)
	2013-2017	All	495	94.8% (92.3%; 97.3%)	91.8% (88.1%; 95.7%)	91.9% (87.3%; 96.9%)	480	97.0% (95.0%; 99.2%)	93.5% (90.1%; 97.1%)	93.0% (88.3%; 97.9%)
	2018-2022	All	529	98.2% (96.3%; 100.2%)	92.4% (88.5%; 96.5%)	94.5% (89.2%; 100.0%)	532	98.5% (96.9%; 100.2%)	97.9% (95.1%; 100.8%)	97.3% (92.7%; 102.2%)
ADC	2008-2012	All	2,465	52.1% (50.0%; 54.2%)	31.3% (29.3%; 33.4%)	27.1% (25.0%; 29.3%)	1,769	51.7% (49.3%; 54.2%)	33.2% (30.9%; 35.8%)	29.2% (26.7%; 31.9%)
		I	460	84.0% (80.2%; 88.0%)	73.7% (68.6%; 79.2%)	70.3% (64.3%; 76.9%)	343	87.0% (82.9%; 91.3%)	77.1% (71.3%; 83.4%)	73.2% (66.2%; 80.9%)
		II	415	74.6% (70.2%; 79.4%)	52.8% (47.5%; 58.7%)	46.4% (40.8%; 52.9%)	268	73.7% (68.2%; 79.6%)	54.7% (48.3%; 62.0%)	49.2% (41.9%; 57.6%)
		III	375	63.5% (58.5%; 68.9%)	29.5% (24.8%; 35.1%)	20.4% (16.2%; 25.7%)	227	64.0% (57.8%; 70.9%)	31.9% (26.0%; 39.2%)	22.7% (17.3%; 29.8%)
		IV	636	30.1% (26.6%; 34.0%)	6.1% (4.4%; 8.5%)	3.8% (2.4%; 6.0%)	423	26.1% (22.2%; 30.8%)	5.1% (3.3%; 7.8%)	3.6% (2.0%; 6.2%)
		X/NA	579	27.3% (23.7%; 31.4%)	11.0% (8.4%; 14.4%)	8.6% (6.1%; 12.3%)	508	32.1% (28.0%; 36.6%)	16.2% (12.9%; 20.3%)	13.0% (9.7%; 17.4%)
	2013-2017	All	2,043	54.4% (52.1%; 56.7%)	32.4% (30.1%; 34.8%)	27.8% (25.4%; 30.3%)	1,473	55.1% (52.5%; 57.8%)	33.1% (30.6%; 35.9%)	29.2% (26.5%; 32.1%)
		I	355	84.8% (80.5%; 89.3%)	72.8% (66.8%; 79.4%)	71.9% (64.6%; 80.0%)	253	87.8% (83.1%; 92.8%)	77.8% (71.1%; 85.1%)	75.9% (67.8%; 84.9%)
		II	424	75.0% (70.6%; 79.6%)	50.4% (45.2%; 56.2%)	45.8% (40.0%; 52.4%)	278	78.1% (73.0%; 83.6%)	55.8% (49.4%; 62.9%)	54.2% (47.3%; 62.1%)
		III	334	68.4% (63.3%; 74.0%)	33.7% (28.5%; 39.9%)	22.0% (17.2%; 28.1%)	228	61.8% (55.6%; 68.8%)	26.1% (20.7%; 32.9%)	20.0% (15.0%; 26.6%)
		IV	619	28.6% (25.1%; 32.5%)	5.8% (4.1%; 8.2%)	2.4% (1.4%; 4.3%)	426	31.0% (26.8%; 35.8%)	9.4% (6.9%; 12.7%)	5.8% (3.9%; 8.7%)
		X/NA	311	27.4% (22.6%; 33.1%)	12.4% (8.7%; 17.6%)	8.7% (5.5%; 13.9%)	288	34.3% (28.9%; 40.7%)	12.6% (8.8%; 18.1%)	5.5% (3.0%; 10.0%)
2018-2022	All	1,859	57.7% (55.4%; 60.2%)	36.7% (34.2%; 39.5%)	30.7% (27.7%; 34.1%)	1,299	57.0% (54.2%; 59.9%)	35.0% (32.0%; 38.3%)	29.2% (25.7%; 33.2%)	
	I	338	85.6% (81.1%; 90.2%)	76.1% (69.5%; 83.3%)	72.1% (62.5%; 83.3%)	243	84.1% (78.9%; 89.6%)	73.8% (66.4%; 82.1%)	66.3% (55.8%; 78.7%)	
	II	327	76.5% (71.6%; 81.8%)	58.4% (51.9%; 65.6%)	46.2% (38.0%; 56.1%)	241	73.5% (67.7%; 79.7%)	49.6% (42.3%; 58.2%)	42.4% (34.0%; 52.8%)	
	III	324	71.1% (66.0%; 76.7%)	43.9% (37.9%; 50.8%)	35.9% (29.1%; 44.3%)	214	69.1% (62.8%; 76.1%)	42.6% (35.4%; 51.3%)	30.9% (23.1%; 41.5%)	

Type	Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		IV	704	35.1% (31.7%; 38.9%)	10.6% (8.3%; 13.6%)	6.5% (4.4%; 9.8%)	456	34.6% (30.4%; 39.3%)	8.7% (6.2%; 12.3%)	6.4% (3.9%; 10.4%)
		X/NA	166	33.8% (26.9%; 42.6%)	9.8% (5.5%; 17.4%)	8.0% (4.0%; 15.9%)	145	36.4% (28.8%; 46.1%)	16.1% (9.5%; 27.2%)	13.1% (6.5%; 26.7%)
NENs	2008-2012	All	90	76.9% (68.2%; 86.7%)	65.3% (55.0%; 77.5%)	59.4% (48.0%; 73.6%)	149	88.1% (82.6%; 93.9%)	85.3% (78.6%; 92.5%)	80.0% (72.1%; 88.8%)
		I	19	N<50	N<50	N<50	47	N<50	N<50	N<50
		II	11	N<50	N<50	N<50	5	N<50	N<50	N<50
		III	4	N<50	N<50	N<50	5	N<50	N<50	N<50
		IV	16	N<50	N<50	N<50	8	N<50	N<50	N<50
		X/NA	40	N<50	N<50	N<50	84	91.9% (85.6%; 98.6%)	94.0% (87.2%; 101.3%)	87.2% (77.7%; 97.9%)
				All	146	81.4% (74.9%; 88.5%)	75.6% (67.8%; 84.2%)	77.1% (68.4%; 87.0%)	186	93.0% (88.9%; 97.2%)
		I	44	N<50	N<50	N<50	67	97.2% (92.3%; 102.4%)	101.3% (96.2%; 106.7%)	105.0% (98.2%; 112.4%)
		II	15	N<50	N<50	N<50	15	N<50	N<50	N<50
		III	5	N<50	N<50	N<50	5	N<50	N<50	N<50
		IV	19	N<50	N<50	N<50	6	N<50	N<50	N<50
		X/NA	64	88.7% (80.3%; 98.0%)	85.2% (74.3%; 97.6%)	88.6% (75.7%; 103.7%)	93	91.9% (86.0%; 98.3%)	82.6% (73.8%; 92.4%)	78.2% (68.3%; 89.5%)
2013-2017	2018-2022	All	151	87.9% (82.4%; 93.8%)	76.4% (68.6%; 85.0%)	73.8% (64.7%; 84.2%)	182	90.3% (85.7%; 95.0%)	89.3% (83.7%; 95.3%)	93.2% (87.0%; 99.9%)
		I	67	100.5% (97.6%; 103.5%)	97.2% (89.5%; 105.5%)	99.2% (89.3%; 110.1%)	103	98.6% (95.3%; 102.0%)	97.8% (92.1%; 103.9%)	102.3% (95.1%; 110.0%)
		II	20	N<50	N<50	N<50	14	N<50	N<50	N<50
		III	6	N<50	N<50	N<50	6	N<50	N<50	N<50
		IV	25	N<50	N<50	N<50	13	N<50	N<50	N<50
		X/NA	33	N<50	N<50	N<50	46	N<50	N<50	N<50
				All	89	45.0% (35.5%; 57.1%)	22.3% (14.6%; 34.1%)	16.4% (9.8%; 27.7%)	82	30.4% (21.8%; 42.4%)
		I	8	N<50	N<50	N<50	6	N<50	N<50	N<50
		II	11	N<50	N<50	N<50	13	N<50	N<50	N<50
Other	2008-2012	All	89	45.0% (35.5%; 57.1%)	22.3% (14.6%; 34.1%)	16.4% (9.8%; 27.7%)	82	30.4% (21.8%; 42.4%)	18.3% (11.4%; 29.6%)	10.8% (5.6%; 20.8%)
		I	8	N<50	N<50	N<50	6	N<50	N<50	N<50
		II	11	N<50	N<50	N<50	13	N<50	N<50	N<50

Type	Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		III	10	N<50	N<50	N<50	10	N<50	N<50	N<50
		IV	17	N<50	N<50	N<50	25	N<50	N<50	N<50
		X/NA	43	N<50	N<50	N<50	28	N<50	N<50	N<50
2013-2017	All		62	47.0% (35.6%; 61.9%)	23.7% (14.5%; 38.9%)	20.3% (11.3%; 36.3%)	51	43.6% (31.5%; 60.4%)	22.7% (12.8%; 40.2%)	17.4% (8.6%; 35.3%)
	I		4	N<50	N<50	N<50	5	N<50	N<50	N<50
	II		3	N<50	N<50	N<50	4	N<50	N<50	N<50
	III		14	N<50	N<50	N<50	5	N<50	N<50	N<50
	IV		17	N<50	N<50	N<50	11	N<50	N<50	N<50
	X/NA		24	N<50	N<50	N<50	26	N<50	N<50	N<50
2018-2022	All		65	42.6% (31.7%; 57.2%)	36.4% (24.6%; 53.8%)	39.0% (25.8%; 59.1%)	53	42.6% (30.4%; 59.5%)	30.3% (18.7%; 49.2%)	36.6% (22.5%; 59.4%)
	I		7	N<50	N<50	N<50	5	N<50	N<50	N<50
	II		12	N<50	N<50	N<50	9	N<50	N<50	N<50
	III		4	N<50	N<50	N<50	2	N<50	N<50	N<50
	IV		26	N<50	N<50	N<50	19	N<50	N<50	N<50
	X/NA		16	N<50	N<50	N<50	18	N<50	N<50	N<50

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

6. CANCER MORTALITY



6.1. Gastric cancer mortality: by region

6.1.1. Gastric cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021

Region	N [CR]																				All ages	ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-			
Males																							
Belgium	0	0	0	0	0	1	3	3	2	7	15	29	33	54	59	65	53	56	23	5	408	8.1	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.8]	[0.8]	[0.5]	[1.8]	[3.8]	[7.2]	[9.1]	[17.6]	[22.3]	[37.3]	[40.6]	[72.1]	[81.9]	[91.7]	[7.2]	(7.3; 8.9)	
Brussels	0	0	0	0	0	0	0	0	0	1	2	3	3	1	7	2	6	5	1	1	32	8.9	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.3]	[5.0]	[8.8]	[11.0]	[4.8]	[41.9]	[17.4]	[71.0]	[98.9]	[46.0]	[214.1]	[5.3]	(5.7; 12.0)	
Flanders	0	0	0	0	0	1	2	2	1	4	9	14	21	35	33	44	38	36	17	3	260	8.2	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.0]	[1.0]	[0.5]	[1.9]	[3.8]	[5.7]	[9.5]	[18.6]	[20.4]	[38.5]	[44.1]	[69.6]	[92.8]	[83.8]	[7.9]	(7.2; 9.2)	
Wallonia	0	0	0	0	0	0	1	1	1	2	4	12	9	18	19	19	9	15	5	1	116	7.7	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[0.9]	[0.9]	[1.6]	[3.2]	[9.6]	[7.8]	[18.4]	[22.0]	[39.2]	[25.0]	[71.6]	[66.0]	[71.1]	[6.5]	(6.2; 9.1)	
Females																							
Belgium	0	0	0	0	0	0	2	4	9	4	9	15	11	11	35	33	35	34	25	13	240	3.6	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.1]	[2.4]	[1.1]	[2.3]	[3.7]	[3.0]	[3.4]	[11.8]	[15.5]	[18.9]	[25.1]	[37.7]	[67.6]	[4.1]	(3.2; 4.1)	
Brussels	0	0	0	0	0	0	0	1	2	1	0	2	2	1	1	4	2	2	1	0	19	3.7	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.1]	[4.4]	[2.5]	[0.0]	[6.0]	[6.7]	[4.1]	[4.6]	[24.6]	[14.6]	[19.7]	[17.4]	[0.0]	[3.1]	(2.0; 5.3)	

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Flanders	0	0	0	0	0	0	1	3	3	2	5	7	3	9	22	23	24	25	14	12	153	3.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.4]	[1.4]	[1.0]	[2.2]	[2.9]	[1.4]	[4.7]	[12.6]	[17.3]	[20.7]	[29.4]	[34.9]	[106.8]	[4.6]	(3.1; 4.4)
Wallonia	0	0	0	0	0	0	1	0	4	1	4	6	6	1	12	6	9	7	10	1	68	3.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[3.5]	[0.8]	[3.2]	[4.7]	[5.0]	[0.9]	[11.9]	[9.4]	[16.3]	[17.5]	[49.0]	[16.6]	[3.6]	(2.5; 4.1)

Note: Mortality, as registered with ICD-10 C16.

7. CANCER MORTALITY TRENDS



7.1. Gastric cancer mortality trends: by region

7.1.1. Gastric cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period	
Belgium	N	506	511	500	482	490	469	421	499	496	458	468	472	443	418	397	392	430	408			
	CR	9.9	10.0	9.7	9.3	9.4	8.9	7.9	9.3	9.2	8.4	8.5	8.6	8.0	7.5	7.1	7.0	7.6	7.2			
	ESR2013	14.2	14.0	13.5	12.5	12.5	11.7	10.4	12.1	11.8	10.7	10.6	10.2	9.7	8.8	8.3	8.0	8.6	8.1	-3.4 (-3.9; -2.9)	2004-2021	
Brussels	N	44	43	34	32	38	41	34	33	43	41	38	31	50	38	31	31	36	32			
	CR	9.2	8.9	6.9	6.4	7.5	7.9	6.5	6.1	7.8	7.3	6.7	5.4	8.6	6.5	5.3	5.2	6.0	5.3			
	ESR2013	14.0	12.2	10.1	10.2	11.0	11.4	9.6	9.8	13.4	11.9	11.3	9.0	13.7	10.0	8.3	8.2	9.2	8.9	-1.7 (-3.1; -0.4)	2004-2021	
Flanders	N	328	307	312	295	311	301	277	311	314	287	289	303	257	259	248	253	272	260			
	CR	11.1	10.3	10.4	9.8	10.2	9.8	9.0	10.0	10.0	9.1	9.1	9.5	8.0	8.0	7.7	7.8	8.3	7.9			
	ESR2013	15.3	14.3	14.1	12.5	12.8	12.7	11.5	12.3	12.1	10.9	10.7	10.6	8.8	8.8	8.3	8.3	8.7	8.2	-3.7 (-4.2; -3.1)	2004-2021	
																				-3.6 (-6.2; -0.9)	2004-2008	
																					-3.7 (-4.4; -3.0)	2009-2021
Wallonia	N	134	161	154	155	141	127	110	155	139	130	141	138	136	121	118	108	122	116			
	CR	8.2	9.8	9.3	9.3	8.4	7.5	6.5	9.0	8.1	7.5	8.1	7.9	7.7	6.9	6.7	6.1	6.8	6.5			
	ESR2013	12.1	14.0	13.4	13.0	12.3	10.1	8.7	12.1	10.3	10.0	10.0	9.6	10.3	8.4	7.9	7.2	8.1	7.7	-3.4 (-4.3; -2.4)	2004-2021	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

Note: Mortality, as registered with ICD-10 C16.

7.1.2. Gastric cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	N	338	317	328	319	310	282	302	311	311	284	276	268	270	270	244	238	251	240		
	CR	6.4	5.9	6.1	5.9	5.7	5.1	5.5	5.6	5.5	5.0	4.9	4.7	4.7	4.7	4.2	4.1	4.3	4.1		
	ESR2013	6.3	5.9	5.9	5.7	5.5	5.0	5.1	5.2	5.0	5.0	4.5	4.3	4.2	4.2	4.2	3.6	3.5	3.7	3.6	-3.4 (-3.8; -3.1)
Brussels	N	27	21	15	30	24	31	17	35	18	25	36	25	16	22	21	25	17	19		
	CR	5.2	4.0	2.8	5.6	4.4	5.6	3.0	6.1	3.1	4.2	6.0	4.1	2.6	3.6	3.4	4.1	2.7	3.1		
	ESR2013	4.9	4.1	3.1	5.8	4.2	6.2	3.1	6.8	3.3	4.8	6.5	4.9	3.0	4.1	4.0	5.0	3.1	3.7		
Flanders	N	218	205	221	181	188	182	197	180	199	172	174	158	171	169	138	159	148	153		
	CR	7.1	6.7	7.2	5.8	6.0	5.8	6.2	5.6	6.2	5.3	5.4	4.8	5.2	5.1	4.2	4.8	4.4	4.6		
	ESR2013	7.2	6.7	7.0	5.5	5.8	5.4	5.7	5.1	5.4	4.6	4.6	4.2	4.4	4.4	3.4	3.9	3.5	3.8		
Wallonia	N	93	91	92	108	98	69	88	96	94	87	66	85	83	79	85	54	86	68		
	CR	5.3	5.2	5.2	6.1	5.5	3.9	4.9	5.3	5.2	4.8	3.6	4.6	4.5	4.3	4.6	2.9	4.6	3.6		
	ESR2013	5.3	5.2	5.0	6.0	5.3	3.8	4.7	5.0	4.7	4.2	3.2	4.1	4.1	3.9	4.0	2.5	4.1	3.3		

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

Note: Mortality, as registered with ICD-10 C16.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Mortality is reported by main group of ICD-10 classification.

Recommended reference: Cancer Fact Sheets 2022, Belgian Cancer Registry (BCR), 2025